 Timothy Jenkins
Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 43 | 2025 | 1702 | 7.550 |
Why?
| | Antimicrobial Stewardship | 12 | 2024 | 104 | 4.850 |
Why?
| | Otitis Media | 7 | 2024 | 160 | 3.570 |
Why?
| | Skin Diseases, Bacterial | 7 | 2016 | 21 | 2.750 |
Why?
| | Bacteremia | 9 | 2025 | 194 | 2.680 |
Why?
| | Staphylococcal Infections | 7 | 2025 | 389 | 2.390 |
Why?
| | Practice Patterns, Physicians' | 11 | 2024 | 1267 | 1.950 |
Why?
| | Inappropriate Prescribing | 6 | 2021 | 53 | 1.930 |
Why?
| | Drug Utilization | 5 | 2020 | 171 | 1.930 |
Why?
| | Soft Tissue Infections | 4 | 2018 | 35 | 1.790 |
Why?
| | Staphylococcus aureus | 5 | 2025 | 434 | 1.360 |
Why?
| | Abscess | 4 | 2015 | 73 | 1.360 |
Why?
| | Anti-Infective Agents | 7 | 2020 | 247 | 1.310 |
Why?
| | Ambulatory Care | 6 | 2020 | 504 | 1.270 |
Why?
| | Conjunctivitis | 4 | 2024 | 30 | 1.220 |
Why?
| | Skin Diseases | 3 | 2015 | 143 | 1.140 |
Why?
| | Drug Prescriptions | 3 | 2020 | 247 | 1.120 |
Why?
| | Otitis | 2 | 2024 | 9 | 1.100 |
Why?
| | Hospitalization | 7 | 2017 | 2052 | 1.090 |
Why?
| | Endocarditis, Bacterial | 1 | 2025 | 42 | 0.910 |
Why?
| | Amoxicillin | 1 | 2024 | 30 | 0.870 |
Why?
| | Guideline Adherence | 4 | 2022 | 526 | 0.830 |
Why?
| | Cellulitis | 2 | 2014 | 48 | 0.810 |
Why?
| | Retrospective Studies | 25 | 2025 | 14455 | 0.750 |
Why?
| | Acute Disease | 7 | 2024 | 978 | 0.740 |
Why?
| | Fluoroquinolones | 3 | 2024 | 45 | 0.740 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 569 | 0.740 |
Why?
| | Urinary Tract Infections | 3 | 2018 | 151 | 0.730 |
Why?
| | Inpatients | 3 | 2020 | 462 | 0.700 |
Why?
| | Gram-Negative Bacterial Infections | 2 | 2018 | 45 | 0.680 |
Why?
| | Conjunctivitis, Bacterial | 3 | 2024 | 11 | 0.680 |
Why?
| | Cross Infection | 2 | 2015 | 217 | 0.670 |
Why?
| | Humans | 60 | 2025 | 129248 | 0.670 |
Why?
| | Drug Resistance, Bacterial | 3 | 2017 | 175 | 0.610 |
Why?
| | Substance Abuse, Intravenous | 2 | 2020 | 108 | 0.600 |
Why?
| | Pharyngitis | 1 | 2018 | 25 | 0.590 |
Why?
| | Child | 18 | 2024 | 20773 | 0.580 |
Why?
| | Smartphone | 1 | 2018 | 87 | 0.560 |
Why?
| | Infection Control | 2 | 2017 | 140 | 0.550 |
Why?
| | Nitrofurantoin | 1 | 2017 | 7 | 0.540 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2017 | 13 | 0.540 |
Why?
| | Cystitis | 1 | 2017 | 22 | 0.540 |
Why?
| | Colorado | 9 | 2020 | 4406 | 0.540 |
Why?
| | Emergency Service, Hospital | 5 | 2020 | 1896 | 0.510 |
Why?
| | Administration, Intravenous | 3 | 2025 | 141 | 0.500 |
Why?
| | Mobile Applications | 1 | 2018 | 160 | 0.490 |
Why?
| | Sinusitis | 1 | 2018 | 210 | 0.490 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 27 | 0.470 |
Why?
| | Drug Users | 1 | 2015 | 41 | 0.470 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2014 | 37 | 0.450 |
Why?
| | Medication Therapy Management | 1 | 2015 | 72 | 0.440 |
Why?
| | Female | 29 | 2025 | 68543 | 0.420 |
Why?
| | Arthritis, Infectious | 2 | 2024 | 59 | 0.420 |
Why?
| | Adult | 23 | 2025 | 35495 | 0.420 |
Why?
| | Cohort Studies | 9 | 2024 | 5408 | 0.410 |
Why?
| | Practice Guidelines as Topic | 4 | 2017 | 1497 | 0.410 |
Why?
| | Middle Aged | 19 | 2025 | 31087 | 0.410 |
Why?
| | Male | 26 | 2025 | 63501 | 0.410 |
Why?
| | Osteomyelitis | 2 | 2012 | 121 | 0.400 |
Why?
| | Escherichia coli | 1 | 2017 | 766 | 0.400 |
Why?
| | Administration, Oral | 2 | 2025 | 785 | 0.400 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 3 | 2023 | 219 | 0.390 |
Why?
| | Streptococcus pneumoniae | 2 | 2023 | 159 | 0.390 |
Why?
| | Patient Discharge | 2 | 2017 | 835 | 0.390 |
Why?
| | Community-Acquired Infections | 5 | 2017 | 160 | 0.390 |
Why?
| | Critical Pathways | 1 | 2013 | 80 | 0.380 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2012 | 42 | 0.380 |
Why?
| | Treatment Outcome | 9 | 2025 | 10199 | 0.370 |
Why?
| | Aged, 80 and over | 7 | 2025 | 7055 | 0.370 |
Why?
| | Drug Utilization Review | 3 | 2016 | 57 | 0.370 |
Why?
| | Histoplasmosis | 1 | 2011 | 14 | 0.370 |
Why?
| | Humeral Head | 1 | 2011 | 13 | 0.370 |
Why?
| | Child, Preschool | 9 | 2024 | 10456 | 0.360 |
Why?
| | Fistula | 1 | 2011 | 35 | 0.360 |
Why?
| | Muscular Diseases | 1 | 2011 | 107 | 0.350 |
Why?
| | Arm | 1 | 2011 | 107 | 0.340 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2025 | 1364 | 0.340 |
Why?
| | Ambulatory Care Facilities | 2 | 2024 | 226 | 0.330 |
Why?
| | Debridement | 3 | 2024 | 83 | 0.330 |
Why?
| | Infant | 7 | 2024 | 8975 | 0.320 |
Why?
| | Academic Medical Centers | 4 | 2024 | 474 | 0.310 |
Why?
| | Outpatients | 3 | 2021 | 367 | 0.310 |
Why?
| | Respiratory Tract Infections | 1 | 2013 | 376 | 0.300 |
Why?
| | Aged | 10 | 2025 | 22032 | 0.290 |
Why?
| | Sepsis | 2 | 2024 | 572 | 0.280 |
Why?
| | Hospitals | 3 | 2024 | 630 | 0.280 |
Why?
| | Haemophilus influenzae | 2 | 2024 | 63 | 0.270 |
Why?
| | Prescriptions | 2 | 2018 | 66 | 0.260 |
Why?
| | Drug and Narcotic Control | 2 | 2016 | 28 | 0.250 |
Why?
| | Diabetes Mellitus | 1 | 2014 | 1000 | 0.250 |
Why?
| | Decision Support Techniques | 2 | 2024 | 395 | 0.250 |
Why?
| | Health Services Research | 1 | 2008 | 390 | 0.240 |
Why?
| | Penicillins | 1 | 2025 | 57 | 0.230 |
Why?
| | C-Reactive Protein | 2 | 2024 | 400 | 0.230 |
Why?
| | HIV | 1 | 2006 | 227 | 0.230 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2018 | 248 | 0.230 |
Why?
| | Child Care | 1 | 2024 | 26 | 0.230 |
Why?
| | Crystal Arthropathies | 1 | 2024 | 3 | 0.230 |
Why?
| | Drug Administration Schedule | 3 | 2024 | 768 | 0.220 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 14 | 0.220 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 101 | 0.220 |
Why?
| | Drug Hypersensitivity | 1 | 2025 | 81 | 0.220 |
Why?
| | beta-Lactamases | 1 | 2024 | 41 | 0.220 |
Why?
| | Absenteeism | 1 | 2024 | 47 | 0.220 |
Why?
| | Therapeutic Irrigation | 1 | 2024 | 75 | 0.220 |
Why?
| | Daptomycin | 1 | 2023 | 18 | 0.220 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2025 | 170 | 0.210 |
Why?
| | Pandemics | 2 | 2022 | 1482 | 0.210 |
Why?
| | Program Evaluation | 3 | 2017 | 872 | 0.210 |
Why?
| | Streptococcal Infections | 1 | 2025 | 148 | 0.200 |
Why?
| | Organizational Policy | 2 | 2017 | 79 | 0.200 |
Why?
| | Electronic Health Records | 3 | 2024 | 970 | 0.190 |
Why?
| | Non-Randomized Controlled Trials as Topic | 1 | 2021 | 20 | 0.190 |
Why?
| | Cephalosporins | 2 | 2023 | 40 | 0.180 |
Why?
| | Muscle, Skeletal | 1 | 2011 | 1613 | 0.180 |
Why?
| | Logistic Models | 2 | 2018 | 1984 | 0.180 |
Why?
| | Prospective Studies | 3 | 2022 | 7121 | 0.180 |
Why?
| | Adolescent | 6 | 2024 | 20303 | 0.180 |
Why?
| | Bacterial Infections | 2 | 2020 | 235 | 0.180 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2025 | 367 | 0.180 |
Why?
| | Schools | 1 | 2024 | 439 | 0.180 |
Why?
| | Risk Factors | 5 | 2014 | 9745 | 0.180 |
Why?
| | Private Sector | 1 | 2020 | 50 | 0.170 |
Why?
| | Health Services Accessibility | 1 | 2006 | 899 | 0.150 |
Why?
| | Drug Combinations | 2 | 2024 | 330 | 0.150 |
Why?
| | Mass Screening | 1 | 2006 | 1149 | 0.150 |
Why?
| | Intersectoral Collaboration | 1 | 2018 | 58 | 0.150 |
Why?
| | United States | 4 | 2024 | 13828 | 0.140 |
Why?
| | Hospitals, Teaching | 1 | 2018 | 113 | 0.140 |
Why?
| | Insurance, Health | 1 | 2020 | 265 | 0.140 |
Why?
| | Pneumonia, Bacterial | 2 | 2017 | 115 | 0.140 |
Why?
| | Cross-Sectional Studies | 2 | 2018 | 5045 | 0.140 |
Why?
| | Medical Audit | 1 | 2017 | 74 | 0.130 |
Why?
| | Drug Costs | 1 | 2017 | 100 | 0.130 |
Why?
| | Medical Records | 1 | 2017 | 170 | 0.130 |
Why?
| | Linear Models | 1 | 2018 | 819 | 0.120 |
Why?
| | Decision Support Systems, Clinical | 1 | 2018 | 204 | 0.120 |
Why?
| | Time | 1 | 2015 | 75 | 0.120 |
Why?
| | Drug Resistance, Microbial | 1 | 2015 | 69 | 0.120 |
Why?
| | Treatment Failure | 1 | 2016 | 339 | 0.120 |
Why?
| | Pharmacists | 1 | 2017 | 246 | 0.110 |
Why?
| | Hypokalemia | 1 | 2014 | 24 | 0.110 |
Why?
| | Wound Infection | 1 | 2014 | 29 | 0.110 |
Why?
| | Synovial Fluid | 2 | 2024 | 66 | 0.110 |
Why?
| | Safety Management | 1 | 2015 | 112 | 0.110 |
Why?
| | Diagnosis, Differential | 2 | 2024 | 1430 | 0.110 |
Why?
| | Leukocyte Count | 2 | 2024 | 326 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1095 | 0.100 |
Why?
| | Urinalysis | 1 | 2013 | 75 | 0.100 |
Why?
| | Age Factors | 1 | 2020 | 3140 | 0.100 |
Why?
| | Catheter-Related Infections | 1 | 2013 | 72 | 0.100 |
Why?
| | Diabetic Foot | 1 | 2012 | 25 | 0.100 |
Why?
| | Limb Salvage | 1 | 2012 | 57 | 0.100 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2012 | 81 | 0.090 |
Why?
| | Hospitals, Urban | 1 | 2012 | 129 | 0.090 |
Why?
| | Histoplasma | 1 | 2011 | 12 | 0.090 |
Why?
| | Databases, Factual | 1 | 2017 | 1266 | 0.090 |
Why?
| | HIV Infections | 1 | 2006 | 2721 | 0.090 |
Why?
| | Penicillin G | 1 | 2011 | 7 | 0.090 |
Why?
| | Streptomycin | 1 | 2011 | 16 | 0.090 |
Why?
| | Algorithms | 1 | 2018 | 1613 | 0.090 |
Why?
| | Bacteria | 2 | 2023 | 812 | 0.090 |
Why?
| | Enterococcus faecalis | 1 | 2011 | 26 | 0.090 |
Why?
| | Young Adult | 3 | 2018 | 12388 | 0.090 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2011 | 64 | 0.080 |
Why?
| | Blood | 1 | 2010 | 105 | 0.080 |
Why?
| | Salmonella enteritidis | 1 | 2009 | 18 | 0.080 |
Why?
| | Salmonella Food Poisoning | 1 | 2009 | 12 | 0.080 |
Why?
| | Food Handling | 1 | 2009 | 60 | 0.080 |
Why?
| | Salmonella Infections | 1 | 2009 | 54 | 0.080 |
Why?
| | Molecular Epidemiology | 1 | 2009 | 63 | 0.080 |
Why?
| | Incidence | 1 | 2015 | 2636 | 0.080 |
Why?
| | Critical Care | 1 | 2013 | 551 | 0.070 |
Why?
| | Fever | 2 | 2024 | 298 | 0.070 |
Why?
| | Occupational Diseases | 1 | 2009 | 138 | 0.070 |
Why?
| | Endocarditis | 1 | 2008 | 37 | 0.070 |
Why?
| | DNA, Bacterial | 1 | 2009 | 321 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5382 | 0.070 |
Why?
| | Ultrasonography | 1 | 2011 | 713 | 0.070 |
Why?
| | Recurrence | 1 | 2010 | 1005 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2011 | 423 | 0.070 |
Why?
| | Infectious Disease Medicine | 2 | 2016 | 12 | 0.060 |
Why?
| | Epidemiology | 2 | 2016 | 15 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 2013 | 710 | 0.060 |
Why?
| | Radiography | 1 | 2008 | 794 | 0.060 |
Why?
| | Echocardiography | 1 | 2008 | 629 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2024 | 1837 | 0.060 |
Why?
| | Haemophilus Infections | 1 | 2024 | 39 | 0.060 |
Why?
| | Ceftazidime | 1 | 2024 | 6 | 0.060 |
Why?
| | Carbapenems | 1 | 2024 | 23 | 0.050 |
Why?
| | Streptococcus agalactiae | 1 | 2025 | 93 | 0.050 |
Why?
| | Aztreonam | 1 | 2023 | 10 | 0.050 |
Why?
| | Interrupted Time Series Analysis | 1 | 2023 | 53 | 0.050 |
Why?
| | Nasopharynx | 1 | 2023 | 68 | 0.050 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2023 | 51 | 0.050 |
Why?
| | Family Characteristics | 1 | 2024 | 178 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2008 | 727 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2024 | 347 | 0.050 |
Why?
| | ROC Curve | 1 | 2024 | 502 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2022 | 86 | 0.050 |
Why?
| | Reoperation | 1 | 2024 | 541 | 0.050 |
Why?
| | Focus Groups | 1 | 2023 | 450 | 0.040 |
Why?
| | Health Facilities | 1 | 2020 | 79 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3386 | 0.040 |
Why?
| | Coagulase | 1 | 2018 | 6 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 1875 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2018 | 68 | 0.040 |
Why?
| | Staphylococcus | 1 | 2018 | 74 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2018 | 271 | 0.040 |
Why?
| | Confidence Intervals | 1 | 2018 | 316 | 0.040 |
Why?
| | Cost Savings | 1 | 2017 | 78 | 0.030 |
Why?
| | Clinical Studies as Topic | 1 | 2017 | 6 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2024 | 3377 | 0.030 |
Why?
| | Bacteriological Techniques | 1 | 2017 | 69 | 0.030 |
Why?
| | Pharmacy Service, Hospital | 1 | 2017 | 89 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3079 | 0.030 |
Why?
| | Research Personnel | 1 | 2017 | 155 | 0.030 |
Why?
| | Patient-Centered Care | 1 | 2020 | 505 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 508 | 0.030 |
Why?
| | Leadership | 1 | 2017 | 353 | 0.030 |
Why?
| | Pregnancy | 1 | 2025 | 6391 | 0.020 |
Why?
| | Drug Synergism | 1 | 2011 | 370 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 399 | 0.020 |
Why?
| | Contact Tracing | 1 | 2009 | 23 | 0.020 |
Why?
| | Food Contamination | 1 | 2009 | 44 | 0.020 |
Why?
| | Restaurants | 1 | 2009 | 20 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2012 | 1199 | 0.020 |
Why?
| | Minnesota | 1 | 2009 | 149 | 0.020 |
Why?
| | Feces | 1 | 2009 | 441 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2009 | 349 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2012 | 4886 | 0.010 |
Why?
|
|
Jenkins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|